SALT LAKE CITY, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that two abstracts have been selected for presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting, being held September 12-15, 2009, in San Francisco, CA.. Presentations will disclose new findings about MPC-4326, a Myriad Pharmaceuticals’ drug candidate being developed as an oral treatment of human immunodeficiency virus 1 (HIV-1) infection.
